Patient is healthy with no chronic disease or significant risk factors [16%].

Similar documents
Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Depok-Indonesia STEPS Survey 2003

The Latest Generation of Clinical

2017 Employee Wellness Health Assessment Report

Epidemiologic Measure of Association

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Metabolic Syndrome and Chronic Kidney Disease

Know Your Number Aggregate Report Single Analysis Compared to National Averages

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

SBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

ASSeSSing the risk of fatal cardiovascular disease

Blood Pressure LIMBO How Low To Go?

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

A cohort study to find Incidence of Peripheral Arterial Disease in

Adult Diabetes Clinician Guide NOVEMBER 2017

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Hypertension JNC 8 (2014)

TRIple pill vs. Usual care Management for Patients with mild-to-moderate Hypertension

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

The Rice Diet of Central Florida

Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.

Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

EXS 145 Guidelines for Exercise Testing & Prescription

WIN QUARTERLY UTILIZATION REPORT 7/1/2010 TO 12/31/2010. EXPERTISE PARTNERSHIP V A L U E April 20, 2011

Supplement materials:

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Cardiovascular Risk Assessment and Management Making a Difference

Hypertension Guidelines JNC Recommendations. Robert E. Bulow DO FACOI, FACC

The Role of Health Information Technology in Implementing Disease Management Programs

Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient

Integrative Medicine Group Visits: A New Model of Care for Managing Health and Well-Being Katherine Gergen Barnett, MD Diane Rogers June 25, 2015

SUPPLEMENTAL MATERIAL

Randomized Design of ALLHAT BP Trial

What is hypertension?

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

Update on New RCHC Relevant and BridgeIT Reports. Redwood Community Health Coalition Data Group Webinar November 13, 2018 By Ben Fouts, Data Analyst

Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Objectives. Describe results and implications of recent landmark hypertension trials

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Wisconsin Chronic Disease Quality Improvement Project. HEDIS 2017 Summary Data

Summary of 2012/13 QOF Changes

Provider Perspective of Quality Measurement

Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies

Impact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients

Methods. Background and Objectives STRADIVARIUS

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Supplementary Online Content

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Economics of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol

The Sound of Atherosclerosis: Voice Signal Characteristics are Independently Associated with Coronary Artery Disease

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

The target blood pressure in patients with diabetes is <130 mm Hg

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

Corporate Health Screening

DM type. Diagnostic method of DR. fluorescein angiography; Ophthalmoscopy. ophthalmoscopic examination. fundus photography; Ophthalmoscopy

Management of Hypertension in the Diabetic Patient:

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise **

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

The Role of Physical Activity in Cardiometabolic Health

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

SPECIFICATION FINAL. Electronic Medical Records. Appendix C Chronic Disease Management Requirements. OntarioMD Inc.

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

Endocrinology TeleECHO Clinic Case Presentation Form

Understand obesity/overweight definition Understand medical consequences How to better evaluate and manage obese/overweight pediatric patients

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

SUPPLEMENTAL MATERIAL. Number of patients 14

October 2013 Employer Worksite Wellness Webinar. Experience. Wellness. Everywhere.

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Supplemental Table 1. Study design and participant characteristics.

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Identification of subjects at high risk for cardiovascular disease

Association Between Hypertension and Coronary Artery Disease as Assessed by Coronary Computed Tomography

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

Fructose, Uric Acid and Hypertension in Children and Adolescents

6/10/2016. Hui-Chun Hsu

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

Managing HTN in the Elderly: How Low to Go

Transcription:

AAFP Risk Level 1 Patient is healthy with no chronic disease or significant risk factors [16%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II o Coronary Artery Disease o Heart Failure o Hypertension o Chronic Kidney Disease o Hyperlipidemia Never or non-smoker AND only social drinker or not at all PHQ9: No or minimal depression score Biometrics within normal limits (WNL): o HbA1c < 5.6% o Total Cholesterol < 200 o Triglycerides < 150 o BMI (age 18+) >=18.5kg/m2 and <=25kg/m2 1

AAFP Risk Level 2 Patient is healthy with no known chronic disease but demonstrates warning signs or other significant risk factors for developing chronic disease [3%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II o Coronary Artery Disease o Heart Failure o Hypertension o Chronic Kidney Disease o Hyperlipidemia Smoker and/or positive for alcohol use/abuse With one or more of the following risk factors: PHQ9: Mild or moderate depression score Biometrics: o Elevated Fasting Glucose > 90 and < 110 o Total Cholesterol > 160 and < 200 o Elevated Blood Pressure SBP > 136 and DBP > 86 o Abnormal BMI (age 18+) <=18.5kg/m2 or >=25kg/m2 2

AAFP Risk Level 3 Patient has one or more chronic diseases with significant risk factors, but is stable or at desired treatment goals [56%]. One or more chronic problems AND associated WNL biometrics: o Depression o Diabetes Type I or Type II o CAD o Heart Failure o Hypertension o Chronic Kidney Disease (Stage 4 or 5 or 6) o Hyperlipidemia AND biometrics WNL o Total Cholesterol < 200 and Triglycerides < 150 o HbA1c < 7 o BP < 140/90 o PHQ9 score of No, Minimal, or Mild (if available) 3

AAFP Risk Level 4 Patient has one or more chronic diseases, with significant risk factors, and is unstable or not at desired treatment goals [22%]. One or more chronic problems AND associated abnormal biometric o CAD with Total Cholesterol > 200 and Triglycerides > 150 o Diabetes with HbA1c > 7.2 o HTN with BP >= 140/90 o HF with BP >= 140/90 o Depression with PHQ9 score of Moderate or Severe Specified chronic conditions with abnormal biometric ONLY otherwise, see Risk Level 3. 4

AAFP Risk Level 5 Patient has multiple chronic diseases, with significant risk factors, complications, and/or complex treatment [10%]. Two or more chronic problems in patient s active problem list AND associated abnormal biometrics: o CAD with Total Cholesterol > 200 and Triglycerides > 150 o Diabetes with HbA1c > 9 o HTN with BP >= 140/90 o HF with BP >= 140/90 o Depression with PHQ9 score of Moderate or Severe o Chronic Kidney Disease (Stage 4 or 5 or 6) o Hyperlipidemia (with total cholesterol >200) o PHQ9: Moderate or severe depression score (regardless of depression diagnosis) 5

AAFP Risk Level 6 Patient has a catastrophic or complex condition in which health may or may not be able to be restored [0.5%]. Four or more chronic problems in patient s active problem list o CAD with Total Cholesterol > 200 and Triglycerides > 150 o Diabetes with HbA1c > 9 o HTN with BP >= 140/90 o HF with BP >= 140/90 o Depression with PHQ9 score of Moderate or Severe o Chronic Kidney Disease (Stage 4 or 5 or 6) o Hyperlipidemia (with total cholesterol >200) AND PHQ9: Moderate or severe depression score (regardless of depression diagnosis) 6